Business News • PR NewsWire • Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696

Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696

Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696

EAST HANOVER, N.J., Aug. 11, 2014 /PRNewswire/ -- New data revealing the reduction in cardiovascular (CV) deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction (HF-REF) will be presented at the world's largest cardiology congress, the European...

View More : http://www.prnewswire.com/news-releases/novartis-to-showcase-heart-failure-leadership-at-esc-congress-2014-with-results-...

Releted News by prnewswire

Beeline Announces Merger With OnForce

Beeline annonce la fusion avec OnForce

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)